SIC 2834 – Pharmaceutical Preparations
Valuation | |
---|---|
Market Cap ($M) | 67.63 |
Enterprise Value ($M) | -60.94 |
Book Value ($M) | 145.70 |
Book Value / Share | 3.02 |
Price / Book | 0.46 |
NCAV ($M) | 124.70 |
NCAV / Share | 2.58 |
Price / NCAV | 0.54 |
Profitability (mra) | |
---|---|
Return on Invested Capital (ROIC) | -0.17 |
Return on Assets (ROA) | -0.16 |
Return on Equity (ROE) | -0.31 |
Liquidity (mrq) | |
---|---|
Quick Ratio | 11.62 |
Current Ratio | 11.62 |
Balance Sheet (mrq) ($M) | |
---|---|
Current Assets | 136.53 |
Assets | 157.53 |
Liabilities | 11.83 |
Debt | n/a |
Equity | n/a |
Income Statement (mra) ($M) | |
---|---|
Revenue | 0.00 |
Operating Income | -141.45 |
Net Income | -24.34 |
Earnings Per Share Basic And Diluted | n/a |
Cash Flow Statement (mra) ($M) | |
---|---|
Cash From Operations | -116.93 |
Cash from Investing | -0.10 |
Cash from Financing | 124.47 |
(click for more detail) |
File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
---|---|---|---|---|
13G/A | Nachtrab Matthew | 4.70 | -12.81 | |
13G/A | Barbier Remi | 4.20 | -17.00 |
Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
---|---|---|---|---|
(click for more detail) |
Date | Insider Trades | Code | Shares | Value |
---|---|---|---|---|
(click for more detail) |
File Date | Form | SEC Filings |
---|---|---|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K (Mark One) | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q | ||
(click for more detail) |
Short Volume | |||
---|---|---|---|
Market Date | Short Volume | Total Volume | Short Volume Ratio |
274,501 | 1,101,541 | 24.92 | |
170,859 | 611,360 | 27.95 | |
383,600 | 1,105,267 | 34.71 | |
436,482 | 1,135,173 | 38.45 | |
(click for more detail) |
Similar Companies | |
---|---|
RVPH – Reviva Pharmaceuticals Holdings, Inc. | RZLT – Rezolute, Inc. |
SABS – SAB Biotherapeutics, Inc. | SBFM – Sunshine Biopharma, Inc. |
SCLX – Scilex Holding Company |